Efficacy and outcomes of transobturator tension-free vaginal tape with or without concomitant pelvic floor repair surgery for urinary stress incontinence: five-year follow-up

Tracy SM Law *, Rachel YK Cheung, Tony KH Chung, Symphorosa SC Chan

ABSTRACT

Objectives: To compare the 5-year subjective and objective outcomes of transobturator tension-free vaginal tape alone versus the same procedure with concomitant pelvic floor repair surgery for pelvic organ prolapse in women with urinary stress incontinence.

Design: Prospective cohort study.

Setting: Urogynaecology unit at a university hospital in Hong Kong.

Patients: Of 218 women, 96 (44%) received transobturator tension-free vaginal tape alone and 122 (56%) received transobturator tension-free vaginal tape with concomitant pelvic floor repair surgery from September 2004 to December 2009. The women were followed up annually for up to 5 years after the operation.

Main outcome measures: The 5-year subjective and objective cure rates were assessed. Subjective cure was defined as no urine loss during physical activity and objective cure was defined as no urine leakage on coughing during urodynamic study.

Results: Overall, 88 women receiving transobturator tension-free vaginal tape alone and 101 women receiving transobturator tension-free vaginal tape with concomitant pelvic floor repair surgery were followed up for 5 years after operation. The subjective and objective cure rates of the two groups were 70.5% versus 94.1% (P<0.01) and 80.3% versus 85.7% (P=0.58), respectively.

Conclusions: Transobturator tension-free vaginal tape is an effective treatment for urinary stress incontinence in women who received it alone or with concomitant pelvic floor repair surgery for pelvic organ prolapse, providing high subjective and objective efficacy for up to 5 years after operation. Transobturator tension-free vaginal tape with concomitant pelvic floor repair surgery achieved similar, if not better, long-term outcome compared with transobturator tension-free vaginal tape alone.

Introduction

Urinary stress incontinence (USI) is a common distressing problem affecting women worldwide. The prevalence of USI ranges from 19% to 55% for different age-groups and communities with a prevalence of 33.8% in Hong Kong.1-4 It has a significant adverse impact on quality of life for 12% of women with the condition in Hong Kong.3-5 Surgical treatment with tension-free vaginal tape (TVT) is a known effective and durable procedure for patients in whom conservative treatment with pelvic floor exercises is unsuccessful.6 Retropubic TVT was first introduced in 1996 and long-term follow-up success rates of up to 77% have been reported 11 years after the procedure.6 However, TVT is associated with risk of bladder, urethra and vessel injuries, and voiding dysfunction.7 The development of transobturator TVT (TO-TVT)
因壓力性尿失禁接受經閉孔無張力陰道懸吊手術，及同時接受骨盆底手術的女性的療效評估：術後五年跟進報告

羅思敏、張優嘉、鍾國衡、陳丞智

目的：比較因壓力性尿失禁接受經閉孔無張力陰道懸吊手術，及同時接受骨盆底手術兩組婦女術後五年的主觀性及客觀性療效評估。

設計：前瞻性隊列研究。

安排：香港一所大學教學醫院的泌尿婦科部門。

患者：對218名婦女於2004年9月至2009年12月期間接受經閉孔無張力陰道懸吊手術；其中96名（44%）婦女只接受經閉孔無張力陰道懸吊手術，另122名（56%）婦女因骨盆內器官膨出而同時接受骨盆底手術。

主要結果測量：於術後五年作出主觀性及客觀性療效評估。主觀性根治的定義為在日常生活中沒有尿失禁的情況；客觀性根治的定義為於尿動力學檢查時沒有尿失禁的情況。

結果：對88名只接受經閉孔無張力陰道懸吊手術的婦女及101名同時接受骨盆底手術的婦女隨訪五年。比較只接受經閉孔無張力陰道懸吊手術的婦女及同時接受骨盆底手術的婦女，其主觀性根治率分別為70.5%及94.1%（P<0.01）；其客觀性根治率分別為80.3%及85.7%（P=0.58）。

結論：無論單一進行經閉孔無張力陰道懸吊手術或同時進行骨盆底手術，經閉孔無張力陰道懸吊手術治療壓力性尿失禁於術後五年仍能达到高治癒率及同等根治療效。與只是進行單一經閉孔無張力陰道懸吊手術比較，同時進行骨盆底手術至少能達至相同的療效。

Methods

This was a prospective study involving all women with USI presenting to the out-patient clinic of a university hospital. All data were collected prospectively and input to a database established in 1996. There were 218 women with USI who received TO-TVT between 1 September 2004 and 31 December 2009. Ethics approval was obtained from the Institutional Review Board to conduct multifaceted analysis of this database (Clinical Research Ethics: CRE-2009.080).

Demographic information was obtained from all women with USI, followed by physical examination, including the standard POP quantification assessment, in the out-patient clinic. All women underwent standard urodynamic investigation, including uroflowmetry and filling and voiding cystometry following standards published by the International Continence Society10 with a Dantec Menuet (from 2004-2009; Dantec Medical A/S, Skovlunde, Denmark) or Maquet Radius (from 2009-2013; Maquet GmbH & Co. KG, Rastatt, Germany) multichannel urodynamic machine.

Women with USI who did not improve after pelvic floor exercise were offered TO-TVT. Women who had USI only underwent TO-TVT surgery, while women with both USI and POP received TO-TVT and concomitant PFR surgery. Vaginal hysterectomy and anterior or posterior colporrhaphy were performed accordingly as PFR surgery. Women with a history of predominant detrusor overactivity (DO), previous continence procedures, or transvaginal mesh repair for POP were excluded from the study. Women with mental incapacity were also excluded.

Women had either TOT (outside-in technique; Monarc Subfascial Hammock, American Medical Systems Inc., Minnetonka [MN], US) performed from September 2004 to June 2006 or TVT-O (inside-out technique; Gynecare TVT obturator system, Ethicon Inc [NJ], US) performed from July 2006 to December 2009 in the same urogynaecology centre. The change from TOT to TVT-O was because TVT-O was becoming available. In this study, 124 women underwent TOT and 94 women underwent TVT-O. Cheung et al11 reported TOT and TVT-O had high and similar subjective and objective efficacy (81%-84%). All procedures were performed or supervised by a urogynaecologist according to the original techniques.12,13 Cystoscopy was performed after the procedure to identify any bladder or urethral injury. The urinary catheter was removed the next day, voiding volume and pattern was reviewed, and post-voiding residual urine was measured. Women were discharged if residual urine was less than 100 mL.

Women were followed up 2 months after operation and then reviewed annually for 5 years. They were assessed subjectively by asking whether their USI symptoms became ‘better’, ‘same’, or ‘worse’. If there was no urine leakage when performing bladder or urethral injury. The urinary catheter was removed the next day, voiding volume and pattern was reviewed, and post-voiding residual urine was measured. Women were discharged if residual urine was less than 100 mL.

Women were followed up 2 months after operation and then reviewed annually for 5 years. They were assessed subjectively by asking whether their USI symptoms became ‘better’, ‘same’, or ‘worse’. If there was no urine leakage when performing bladder or urethral injury. The urinary catheter was removed the next day, voiding volume and pattern was reviewed, and post-voiding residual urine was measured. Women were discharged if residual urine was less than 100 mL.
physical activities, the women were regarded as having ‘subjective cure’ of the USI. Those who responded ‘better’ but had persistent or recurrent USI symptoms were regarded as ‘subjective better’, irrespective of the frequency and amount of urinary leakage. Patients were asked whether they had voiding difficulty, urgency, groin or vaginal pain, or dyspareunia. Physical examination was conducted to check for POP and vaginal tape erosion. Urodynamic study was repeated at 1 and 5 years to assess the objective outcome. Severity of USI was classified according to the degree of urine leakage in the cough stress test: mild (following a series of coughs), moderate (with a few coughs), and marked (with a single cough). Objective cure was defined as no urine leakage upon coughing during urodynamic study. The cough stress test is a well-established test for USI with sensitivity of 98% and specificity of 100%. However, there was no standard set to categorise the severity of USI during urodynamic study. Thus, cough stress test was used to further categorise the severity of USI. Detrusor overactivity was defined as occurrence of involuntary detrusor contractions of >15 cm H2O during filling cystometry. Overactive bladder (OAB) was defined as urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection or other obvious pathology. Patients who did not return for follow-up were contacted and offered another appointment. If they defaulted again, they were interviewed over the telephone using the same set of questions to assess subjective outcome. Follow-up would be ceased if there was no significant problem after the 5-year follow-up.

Data were analysed using the Statistical Package for the Social Sciences (Windows version 17.0; SPSS Inc, Chicago [IL], US). Descriptive statistics of data were presented as mean ± standard deviation or number (%). Categorical variables were compared using Chi squared test or Fisher’s exact test. Continuous variables were compared using independent sample t test. A P value of <0.05 was considered statistically significant.

**Results**

Of 218 women who underwent TO-TVT between 1 September 2004 and 31 December 2009, 96 (44%) women had USI only and underwent TO-TVT alone, while 122 (56%) women had USI and POP and underwent TO-TVT with concomitant PFR surgery. The PFR surgery was usually vaginal hysterectomy with anterior colporrhaphy. For preoperative data (Table 1), women who underwent TO-TVT and PFR surgery were older (mean, 65.6 vs 54.3 years; P<0.01), had higher parity (mean, 3.9 vs 2.6; P<0.01), and had more DO (11.5% vs 2.1%; P=0.02).

At 1 year after surgery, 197 (90.4%) women were reviewed at follow-up and 186 (85.3%) had urodynamic study. At 5 years, 189 (86.7%) women were either reviewed at follow-up or contacted by telephone (20 women) and 122 (56.0%) had urodynamic study. The mean follow-up times were similar: 59.3 ± 8.0 months for the TO-TVT group and 58.6 ± 8.0 months for the TO-TVT with concomitant PFR surgery group.

The subjective cure rate at 1 year was 78.0% for

<table>
<thead>
<tr>
<th>TABLE 1. Patients’ demographics</th>
<th>All (n=218)</th>
<th>TO-TVT (n=96)</th>
<th>TO-TVT with concomitant PFR surgery (n=122)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>60.5 ± 12.7</td>
<td>54.3 ± 10.6</td>
<td>65.6 ± 11.9</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>25.2 ± 3.9</td>
<td>25.4 ± 3.6</td>
<td>25.3 ± 4.2</td>
<td>0.80</td>
</tr>
<tr>
<td>Menopause</td>
<td>146 (67.0)</td>
<td>47 (49.0)</td>
<td>99 (81.1)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>No. of vaginal births</td>
<td>3.3 ± 1.8</td>
<td>2.6 ± 1.4</td>
<td>3.9 ± 1.9</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Biggest birth weight (kg)</td>
<td>3.4 ± 0.7</td>
<td>3.4 ± 0.8</td>
<td>3.3 ± 0.6</td>
<td>0.33</td>
</tr>
<tr>
<td>Previous prolapse surgery</td>
<td>4 (1.8)</td>
<td>1 (1.0)</td>
<td>3 (2.5)</td>
<td>0.40</td>
</tr>
<tr>
<td>Previous hysterectomy</td>
<td>10 (4.6)</td>
<td>4 (4.2)</td>
<td>6 (4.9)</td>
<td>0.53</td>
</tr>
<tr>
<td>Preoperative OAB syndrome</td>
<td>71 (32.6)</td>
<td>35 (36.5)</td>
<td>36 (29.5)</td>
<td>0.37</td>
</tr>
<tr>
<td>Preoperative DO</td>
<td>16 (7.3)</td>
<td>2 (2.1)</td>
<td>14 (11.5)</td>
<td>0.02</td>
</tr>
<tr>
<td>Type of TVT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOT</td>
<td>124 (56.9)</td>
<td>51 (53.1)</td>
<td>73 (59.8)</td>
<td>0.39</td>
</tr>
<tr>
<td>TVT-O</td>
<td>94 (43.1)</td>
<td>45 (46.9)</td>
<td>49 (40.2)</td>
<td>0.39</td>
</tr>
</tbody>
</table>

Abbreviations: DO = detrusor overactivity; OAB = overactive bladder; PFR = pelvic floor repair; SD = standard deviation; TO-TVT = transobturator TVT; TOT = outside-in technique of TVT; TVT = tension-free vaginal tape; TVT-O = inside-out technique of TVT
the TO-TVT group and 86.8% for the TO-TVT with concomitant PFR surgery group (Table 2); respective objective cure rate at 1 year was 80.7% and 87.4%. There was no statistical difference between the two groups. At 5 years, the subjective cure rate was 70.5% for the TO-TVT group and 94.1% for the TO-TVT with concomitant PFR surgery group. Women with TO-TVT with concomitant PFR surgery had statistically higher satisfaction. There was no difference in the objective outcome for the two groups at 5 years (80.3% vs 85.7%). After combining subjective cure and subjective better as one group for overall improvement of USI after surgery, the TO-TVT with concomitant PFR surgery group had significantly higher subjective improvement at 5 years (P=0.04). None required second operation for their USI during the 5-year follow-up.

In the study group, 10.2% and 20.6% had de-novo OAB at 1 and 5 years, respectively, and there was no statistical difference between the TO-TVT group and TO-TVT with concomitant PFR surgery group. More women developed de-novo DO at 5 years in the TO-TVT with concomitant PFR surgery group compared with TO-TVT group (14.3% vs 4.5%; P=0.12), although it did not reach statistical difference. Eight (8.3%) women in the TO-TVT group with de-novo OAB required medical treatment for their symptoms and five (4.1%) women in the TO-TVT with concomitant PFR surgery group required treatment (P=0.30).

No neurological complications resulting from the surgery were reported. Three women (two in the concomitant PFR surgery group and one in the TO-TVT alone group) had tape erosion requiring excision of the exposed tape (Table 3). The patients all presented with vaginal pain. The exposed tape was cut and the vaginal skin was repaired under local or regional anaesthesia. All three women had no recurrence of USI after tape excision at the 5-year follow-up. Two women (both from TO-TVT alone group) developed voiding difficulty with OAB symptoms and the tape was cut at 4 months and 18 months after the operation, respectively. Their voiding problem was resolved and both had no recurrence of USI after tape release. One woman

### Table 2: Subjective and objective outcomes at 1-year and 5-year follow-ups

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Total (n=218)</th>
<th>TO-TVT only (n=106)</th>
<th>TO-TVT with concomitant PFR surgery (n=112)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subjective</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USI Cure</td>
<td>n=197/218 (90.4)</td>
<td>n=91/96 (94.8)</td>
<td>n=106/122 (86.9)</td>
<td></td>
</tr>
<tr>
<td>Better</td>
<td>163 (82.7)</td>
<td>71 (78.0)</td>
<td>92 (86.8)</td>
<td>0.15</td>
</tr>
<tr>
<td>Same</td>
<td>25 (12.7)</td>
<td>16 (17.6)</td>
<td>9 (8.5)</td>
<td>0.09</td>
</tr>
<tr>
<td>Worse</td>
<td>7 (3.6)</td>
<td>3 (3.3)</td>
<td>4 (3.8)</td>
<td>0.58</td>
</tr>
<tr>
<td>De-novo OAB</td>
<td>2 (1.0)</td>
<td>1 (1.1)</td>
<td>1 (0.9)</td>
<td>0.71</td>
</tr>
<tr>
<td><strong>Objective</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USI No</td>
<td>n=186/218 (85.3)</td>
<td>n=83/96 (86.5)</td>
<td>n=103/122 (84.4)</td>
<td></td>
</tr>
<tr>
<td>USI Mild</td>
<td>10 (5.4)</td>
<td>6 (7.2)</td>
<td>4 (3.9)</td>
<td>0.49</td>
</tr>
<tr>
<td>Moderate</td>
<td>10 (5.4)</td>
<td>4 (4.8)</td>
<td>6 (5.8)</td>
<td>1.00</td>
</tr>
<tr>
<td>Severe</td>
<td>9 (4.8)</td>
<td>6 (7.2)</td>
<td>3 (2.9)</td>
<td>0.30</td>
</tr>
<tr>
<td>De-novo DO</td>
<td>10 (5.4)</td>
<td>5 (6.0)</td>
<td>5 (4.9)</td>
<td>0.98</td>
</tr>
</tbody>
</table>

### Table 3: Complications of transobturator tension-free vaginal tape 5 years after surgery

<table>
<thead>
<tr>
<th>Complication</th>
<th>Total (n=189)</th>
<th>TO-TVT only (n=88)</th>
<th>TO-TVT with concomitant PFR surgery (n=101)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tape erosion</td>
<td>3 (1.6)</td>
<td>1 (1.1)</td>
<td>2 (2.0)</td>
<td>0.51</td>
</tr>
<tr>
<td>Voiding problem</td>
<td>2 (1.1)</td>
<td>2 (2.3)</td>
<td>0</td>
<td>0.21</td>
</tr>
<tr>
<td>Groin pain</td>
<td>1 (0.5)</td>
<td>1 (1.1)</td>
<td>0</td>
<td>0.47</td>
</tr>
</tbody>
</table>

Abbreviations: DO = detrusor overactivity; OAB = overactive bladder; PFR = pelvic floor repair; TO-TVT = transobturator tension-free vaginal tape; USI = urinary stress incontinence.

* The denominator for the calculation of de-novo DO was based on the total number of women who had urodynamic study performed at the 1-year and 5-year follow-ups.

Abbreviations: PFR = pelvic floor repair; TO-TVT = transobturator tension-free vaginal tape.
(in the TO-TVT alone group) had groin pain 4 years after the operation and was treated conservatively with analgesics.

**Discussion**

Transobturator TVT has been proven to be safe and highly effective,\(^{11,15}\) and has become a standard treatment for UI. Pelvic floor repair surgery is commonly performed at the same time as continence surgery.\(^{16}\) However, there is limited information comparing the long-term efficacy of TO-TVT in women with or without concomitant PFR surgery. This study evaluated 5-year subjective and objective outcomes in the two treatment groups of women with USI alone and those having USI and POP who required treatment for both conditions.

Women in the TO-TVT with concomitant PFR surgery group were older, had a higher number of vaginal births, and more were menopausal and had DO. This observation is likely due to the age of the women, as risk of DO also increases with age and more women had pre-existing DO in this group.

Subjective cure in our study was defined as feeling completely dry after TO-TVT operation. The 5-year subjective cure rate of the TO-TVT alone group was 70.5%. Although this appears to be lower than in the concomitant PFR surgery group of 94.1%, the result is comparable to most of the published data on long-term efficacy of TO-TVT. Angioli et al\(^{17}\) showed a 62% patient satisfaction rate and 73% objective success rate at 5 years. Abdel-Fattah et al\(^{18}\) also showed a 73% patient-reported success rate for TO-TVT at 3-year follow-up in 238 women.

We hypothesised that women with concomitant PFR surgery had a higher subjective cure rate because anterior colporrhaphy added an anti-incontinence effect. Furthermore, the main symptoms for this group of women might be related to POP so treating their POP could raise their overall satisfaction. Recurrence of POP may mask the symptoms of USI, but this hypothesis requires further analysis, as the recurrence rate of POP was not collected in this study. The above factors may account for the higher subjective cure rate observed, although the objective cure rates were high in both groups.

The 5-year overall subjective and objective cure rates were 83.1% and 82.8%, respectively, which are similar to international figures.\(^{19,20}\) Athanasiou et al\(^{19}\) reported 7-year overall subjective and objective cure rates of 83.5% and 81.5%, which included women who received TO-TVT alone or with concomitant PFR surgery, but there was no statistical comparison between the groups. Tsivian et al\(^{20}\) reported 82.9% versus 85.2% continence rates in patients undergoing TO-TVT alone versus those who received concomitant vaginal surgery at a mean follow-up period of up to 3 years. These studies, however, were either small or had short follow-up durations.

The long-term complication rate of TO-TVT is low. The most commonly encountered morbidity was de-novo DO after TO-TVT (9% at 5 years), which is similar to that reported in the literature.\(^{17,19}\) Athanasiou et al\(^{19}\) reported 7% de-novo urgency 7 years after TVT-O and Angioli et al\(^{17}\) found a 5-year de-novo urgency rate of 6.4%. The higher percentage of women developing de-novo DO at 5 years (9.0%) when compared with 1 year (5.4%) could be attributed to ageing. This difference also suggests that more women had de-novo DO in the prolapse group (14.3%) than in the TO-TVT alone group (4.5%) as the mean age of the prolapse group was higher. Our 5-year study also shows low rates of mesh erosion and voiding dysfunction after operation, and concomitant surgery does not impose higher complication rates.

We recommend TO-TVT with concomitant PFR surgery as the treatment of choice for women with symptomatic POP and USI. A recent meta-analysis showed a reduced risk of postoperative USI after combination surgery (mid-urethral sling with prolapse surgery) relative to prolapse surgery alone (5% vs 23%) for women with prolapse and symptomatic USI.\(^{21}\) In asymptomatic women with prolapse, however, only 7% required subsequent surgery for de-novo USI. Therefore, even with the promising result of combination surgery, it should only be performed in symptomatic incontinent women instead of as routine surgery for all women with prolapse because TO-TVT is not a risk-free procedure. Thus, preoperative evaluation of urinary symptoms and urodynamic study still plays a role in individual treatment planning.

There are limitations in this study. This was not a randomised controlled study and there was lack of blinding when assessing the objective outcomes. There were significant differences between the characteristics of the two groups (Table 1), and further randomised study is warranted to find out whether those factors contribute to the differences observed in subjective outcomes. We lacked a detailed questionnaire to evaluate the subjective cure rate and to assess quality-of-life aspect after the operation. The validated questionnaires in Chinese were only available after the study period.\(^{22,23}\) However, our previous study has confirmed the improvement in quality of life of women receiving continence surgery with or without PFR surgery.\(^{24}\) Although the response rate for subjective outcome measure was high at 5 years (overall response, 86.7%), fewer women (56.0%) returned for objective assessment using urodynamic study at 5 years.

**Conclusions**

Transobturator TVT is an effective treatment for USI.
in women who received it alone or with concomitant PFR surgery. This technique provides high subjective and objective efficacy for up to 5 years with a good safety profile. Transobturator TVT with concomitant PFR surgery achieved similar, if not better, long-term outcomes when compared with TO-TVt alone.

References